CELLCEPT 250 MG CAPSULE

What it is

CELLCEPT 250 MG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as mycophenolate mofetil, under the trade name “CellCept”.

FDA gives its dosage form as capsule and its route as oral.

The labeler, the company named on the label, is Genentech, Inc.

FDA’s Established Pharmacologic Class for it is Antimetabolite Immunosuppressant.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $259.47 for 30 capsules (30 × $8.64903 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

NADAC also lists, on the row of its brand NDCs, what pharmacies pay for the generic equivalent, a different product: $0.13821 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · Why 30 capsules · NADAC explanation codes

All 2 NDCs

• 00004-0259-01 · Genentech, Inc. · $8.64903 per EA · eff. 2026-09-23 filed
• 00004-0259-43 · Genentech, Inc. · $8.64903 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

5 other products in the NADAC file share the FDA nonproprietary name mycophenolate mofetil with CELLCEPT 250 MG CAPSULE.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $8.64903 per EA filed.

Of the 7 other products in FDA’s Antimetabolite Immunosuppressant class priced per EA, 2 have a higher middle NADAC price and 5 a lower one. The one in the middle is MYCOPHENOLATE 500 MG TABLET, at $0.26327 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J7524, for 2026-10-01 to 2026-12-31, comes to $3.00 for 30 capsules, or $0.10 per EA once converted to NADAC’s unit for this product.

Medicare Part B pays for this oral drug at a pharmacy only in specific circumstances CMS sets for this code; most prescriptions are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.0004 per 5 MG.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 capsules? Is it lower than what I would pay through my insurance?
• Is a generic version available, and would it suit me? NADAC lists a generic with the same ingredient, strength and dosage form by FDA: MYCOPHENOLATE 250 MG CAPSULE. Ask your pharmacist or prescriber; do not switch on your own.
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.